Literature DB >> 22752770

Primary vs. secondary recurrent pregnancy loss--epidemiological characteristics, etiology, and next pregnancy outcome.

Efrat Shapira1, Ronit Ratzon, Ilana Shoham-Vardi, Ruslan Serjienko, Moshe Mazor, Asher Bashiri.   

Abstract

OBJECTIVE: To compare epidemiological and obstetric characteristics, etiology and next pregnancy outcomes of women with primary vs. secondary recurrent pregnancy loss (RPL). STUDY
DESIGN: A retrospective cohort study, including 420 patients with two or more consecutive pregnancy losses followed by a subsequent (index) pregnancy, of whom 162 were primary RPL women and 258 were secondary RPL women. All patients were evaluated and treated in the RPL clinic at the Soroka University Medical Center.
RESULTS: Live birth rate in the index pregnancy was not statistically different between primary and secondary RPL women (75.9 and 70.9%, respectively). The only significant difference in the etiology evaluation was in abnormal prolactin levels (14.1% of the primary and 1.4% of the secondary RPL group). Women with primary RPL had, at the index pregnancy, significantly higher rates of preterm delivery, fetal growth restriction, and gestational diabetes mellitus. In a multivariable logistic regression analysis, primary RPL adjusted for maternal age and gravidity, was an independent risk factor for preterm delivery compared with secondary RPL [adjusted OR 2.62, CI (95%) 1.30-5.26].
CONCLUSIONS: The prognosis of the two groups was similar regarding live birth rate at the index pregnancy; however, women with primary RPL were more prone to adverse obstetric and neonatal outcomes.

Entities:  

Mesh:

Year:  2012        PMID: 22752770     DOI: 10.1515/jpm-2011-0315

Source DB:  PubMed          Journal:  J Perinat Med        ISSN: 0300-5577            Impact factor:   1.901


  8 in total

1.  Karyotype evaluation of repeated abortions in primary and secondary recurrent pregnancy loss.

Authors:  T V Nikitina; E A Sazhenova; D I Zhigalina; E N Tolmacheva; N N Sukhanova; I N Lebedev
Journal:  J Assist Reprod Genet       Date:  2020-02-03       Impact factor: 3.412

Review 2.  The Importance of an Evidence-based Workup for Recurrent Pregnancy Loss.

Authors:  Karen J Gibbins; T Flint Porter
Journal:  Clin Obstet Gynecol       Date:  2016-09       Impact factor: 2.190

Review 3.  Parkinson's disease as a result of aging.

Authors:  Manuel Rodriguez; Clara Rodriguez-Sabate; Ingrid Morales; Alberto Sanchez; Magdalena Sabate
Journal:  Aging Cell       Date:  2015-02-09       Impact factor: 9.304

4.  Consecutive successful pregnancies subsequent to intravenous immunoglobulin therapy in a patient with recurrent spontaneous miscarriage.

Authors:  Michael F Diejomaoh; Zainab Bello; Waleed Al Jassar; Jiri Jirous; Kavitha Karunakaran; Asiya T Mohammed
Journal:  Int Med Case Rep J       Date:  2015-12-11

5.  Gestational and perinatal outcomes in recurrent miscarriages couples treated with lymphocyte immunotherapy.

Authors:  Manoel Sarno; Marcelo Borges Cavalcante; Marla Niag; Kleber Pimentel; Ivana Luz; Bianca Figueiredo; Tatiana Michelon; Jorge Neumann; Simone Lima; Isabela Nelly Machado; Edward Araujo Júnior; Ricardo Barini
Journal:  Eur J Obstet Gynecol Reprod Biol X       Date:  2019-05-07

6.  Impact of Recurrent Miscarriage on Maternal Outcomes in Subsequent Pregnancy: The Mutaba'ah Study.

Authors:  Nasloon Ali; Iffat Elbarazi; Saad Ghazal-Aswad; Fatima Al-Maskari; Rami H Al-Rifai; Abderrahim Oulhaj; Tom Loney; Luai A Ahmed
Journal:  Int J Womens Health       Date:  2020-12-08

7.  Etiologic characteristics and index pregnancy outcomes of recurrent pregnancy losses in Korean women.

Authors:  Gi Su Lee; Joon Cheol Park; Jeong Ho Rhee; Jong In Kim
Journal:  Obstet Gynecol Sci       Date:  2016-09-13

8.  Phenome-Wide Analysis of Short- and Long-Run Disease Incidence Following Recurrent Pregnancy Loss Using Data From a 39-Year Period.

Authors:  David Westergaard; Anna Pors Nielsen; Laust Hvas Mortensen; Henriette Svarre Nielsen; Søren Brunak
Journal:  J Am Heart Assoc       Date:  2020-04-17       Impact factor: 5.501

  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.